Attention all areas: non-ADHD indications offer growth potential for Shire’s Vyvanse
This article was originally published in Scrip
Executive Summary
Positive top-line results from the first European Phase III study of Shire’s Vyvanse in children and adolescents with attention deficit hyperactivity disorder (ADHD) is likely to support the product's EU approval. However, given the competition in ADHD from Johnson & Johnson’s well-established Concerta, and the lower drug treatment rates for ADHD in Europe, the growth potential for Vyvanse may lie in the extension of indications beyond ADHD.